Kailera makes history with record-breaking $625m IPO [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
In a 16 April statement, Kailera announced it'd be offering all 39,062,500 of its shares to prospective buyers at a price of $16 per unit – at the top end of the suggested price detailed in its S-1 filing – with the company expected to commence trading on the Nasdaq under the ticker “KLRA” on 17 April. Underwriters will also have 30 days to buy another 5,859,375 shares at $16, leaving another $92.8m up for grabs by the company. Through this IPO, Kailera expects to secure $625m in gross proceeds, which eclipses the expected $458.7m in net proceeds detailed in the S-1 form, making it one of the largest IPOs in biotech history since Moderna's $604m public market debut in 2018. With this new capital in hand, Kailera hopes to take another step closer to the burgeoning obesity market dominated by Eli Lilly and Novo Nordisk – pouring $650m into funding its three-trial, late-stage KaiNETIC programme for lead obesity injectable, ribupatide, into Q2 2028, as per the company's S-1 filing
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo GLP-1 drug shows less lean mass loss than rivals, study says [USA TODAY]USA TODAY
- Novo Nordisk's Wegovy Wins EMA Flexibility In GLP-1 Access Push [Yahoo! Finance]Yahoo! Finance
- Novo obesity drug outperforms Lilly's in preserving lean body mass: study [Seeking Alpha]Seeking Alpha
- Eli Lilly Weight-Loss Pill Prescriptions Near 1,400 in First Week [Yahoo! Finance]Yahoo! Finance
- Lilly's Foundayo hits 1,390 prescriptions in debut week [Yahoo! Finance Canada]Yahoo! Finance Canada
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/13/26 - Form 6-K
- 4/7/26 - Form 6-K
- 3/30/26 - Form 6-K
- NVO's page on the SEC website